Hoffmann-La Roche lands PI against Menarini Diagnostics from UPC

Recently, the local division Düsseldorf issued a preliminary injunction in proceedings between Hoffmann-La Roche and Menarini over CGM devices. Various providers of this lucrative technology are currently in dispute at the UPC.

Glucose-monitoring devices represent a highly competitive market, as diabetes affects millions worldwide. Continuous glucose-monitoring systems (CGM) have become particularly popular, allowing users to monitor their blood-glucose levels continuously via mobile phone. Several companies are currently battling over this technology at the UPC.

F. Hoffmann-La Roche owns EP 1 962 668 B1, which protects a “sandwich sensor for the determination of an analyte concentration”. The patent owner accuses Berlin-Chemie and Menarini of infringing the patent with their products marketed under the brand name GlucoMen iCan. Roche applied for provisional measures at the UPC local division Düsseldorf.

The judges’ panel, consisting of presiding judge Ronny Thomas, judge rapporteur Jule Schumacher and legally qualified judge András Kupecz, granted Hoffmann-La Roche an injunction in the PI proceedings (case ID: ACT_34241/2025/UPC_CFI_712/2025).

At the November hearing, discussion focused strongly on the sensor design, particularly the combination of the electrode system and contact layer. In its judgment, the court explained in detail the design of the sensors which Menarini is no longer permitted to manufacture, import or distribute in Germany, France, and Italy.

Additionally, the company must provisionally reimburse costs of €32,051.20. The UPC set the value in dispute at €1,000,000. According to JUVE Patent sources, Menarini will appeal the decision.